Loading
Drug sensitivity results for the same cell line and drug differ substantially between large screens. Every published cancer drug screen should include a defined panel of reference compounds with published expected activity ranges per reference cell line, reported in a standard format, so results from different labs can be calibrated against each other.
Drug sensitivity results for the same cell line and drug differ substantially between large screens (the CCLE versus GDSC discordance). A defined panel of reference compounds (with expected potency ranges per reference cell line) included in every published screen, and reported in a standard format, would allow cross-study calibration and reveal systematic differences in assay conditions.
Shares A digital passport for every cell culture: identity, contamination status, passage number, Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares Shared reference organoid and PDX panels that every lab can test against, DepMap (Cancer Dependency Map), Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares A digital passport for every cell culture: identity, contamination status, passage number, Preclinical results do not reproduce.
Shares CRISPR functional genomics, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Preclinical results do not reproduce, Lab models that fail to predict what happens in patients.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Preclinical results do not reproduce.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Lab models that fail to predict what happens in patients.